UT Southwestern Harold C. Simmons Comprehensive Cancer Center | Strategic Alliance Partners

Connect with us:

Latest from UT Southwestern Harold C. Simmons Comprehensive Cancer Center


Novel Therapies Provide a Wealth of Individualized Treatment Options in CLL and MCL

October 20, 2022

Farrukh Awan, MD, discusses new agents under investigation in chronic lymphocytic leukemia and mantle cell lymphoma and emphasizes the importance of weighing each drug’s risks and benefits against individual patient needs and preferences to make informed decisions.

Novel Treatments Begin to Rival Transplant in AML and DLBCL

October 18, 2022

Farrukh Awan, MD, discusses transplant and chemotherapy options in frontline diffuse large B-cell lymphoma, the emergence of CAR T-cell therapy in relapsed diffuse large B-cell lymphoma, and available targeted therapies in acute myeloid leukemia.

Novel ADC and CAR T Approaches Broaden the DLBCL Treatment Landscape

October 17, 2022

Praveen Ramakrishnan, MD, MS, discusses the evolution of diffuse large B-cell lymphoma treatment, the implications of key phase 3 studies, and how emerging bispecific T-cell engagers and antibody-drug conjugates may increase treatment accessibility beyond the limitations of CAR T-cell therapy for patients at various disease stages.

Continued Emergence of Targeted Therapies Reinforces Need for Frequent Genetic Testing in NSCLC

August 25, 2022

Although the efficacy of targeted agents and outcomes for patients with genetic mutations can vary, the availability of these treatments adds to the need for genetic testing across all patients with non–small cell lung cancer.

Successful Treatment Options Expand to Earlier Lines in RCC and Urothelial Cancer

June 23, 2022

Tian Zhang, MD, discusses the benefits of multidisciplinary collaboration, how to select the best agents for each patient, and how treatments such as radiation in RCC and bladder-sparing chemoradiation in urothelial cancer fit into the overall treatment paradigms for these diseases.

ARO-HIF2 Lowers HIF2α Expression and Demonstrates Favorable Safety Profile in Clear Cell RCC

May 04, 2022

The investigational RNA interference therapy, ARO-HIF2, reduced levels of hypoxia inducible factor-2 alpha expression and had acceptable tolerability when used in patients with clear cell renal cell carcinoma, according to data from the phase 1b AROHIF21001 trial.